NasdaqGM:URGNBiotechs
What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders
UroGen Pharma recently reported that the U.S. Food and Drug Administration cleared its Investigational New Drug application for UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer, allowing a Phase 1 trial of intravesical administration focused on safety, tolerability, and feasibility to begin.
This IND clearance adds a new oncolytic immunotherapy candidate to UroGen’s uro-oncology pipeline, potentially broadening its future reach beyond bladder cancer into...